Media coverage about Cambrex Corporation (NYSE:CBM) has trended somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cambrex Corporation earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.1735579811218 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have impacted Accern’s scoring:
- Cambrex wins API development award at CPhI Worldwide for second consecutive year (pressreleasepoint.com)
- Cambrex Corporation (CBM) Given Consensus Rating of “Hold” by Analysts (americanbankingnews.com)
- Cambrex Invests in New Small Scale Capacity at Its Charles City, Iowa Facility – Markets Insider (markets.businessinsider.com)
- Cambrex Corp. (CBM) Tops Q3 EPS by 7c, Beats on Revenues; Offers FY17 EPS Mid-Point Below Consensus – StreetInsider.com (streetinsider.com)
Shares of Cambrex Corporation (CBM) opened at $45.90 on Tuesday. Cambrex Corporation has a 12 month low of $42.55 and a 12 month high of $62.95. The company has a market cap of $1,519.24, a P/E ratio of 14.62 and a beta of 2.26.
Cambrex Corporation (NYSE:CBM) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.08. The firm had revenue of $112.60 million during the quarter, compared to analysts’ expectations of $108.44 million. Cambrex Corporation had a net margin of 18.79% and a return on equity of 23.42%. The business’s revenue was up 13.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.47 EPS. research analysts forecast that Cambrex Corporation will post 2.97 EPS for the current year.
Several research firms recently commented on CBM. Craig Hallum reaffirmed a “buy” rating and issued a $60.00 price target (down previously from $70.00) on shares of Cambrex Corporation in a research note on Tuesday, October 31st. ValuEngine downgraded shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Finally, BidaskClub downgraded shares of Cambrex Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, August 24th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $62.33.
WARNING: “Cambrex Corporation (NYSE:CBM) Receiving Somewhat Positive Press Coverage, Study Shows” was published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.truebluetribune.com/2017/11/14/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-cambrex-corporation-cbm-stock-price.html.
In other Cambrex Corporation news, CEO Steven M. Klosk sold 4,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $54.96, for a total value of $219,840.00. Following the transaction, the chief executive officer now owns 87,328 shares of the company’s stock, valued at $4,799,546.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Steven M. Klosk sold 12,000 shares of the stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $51.53, for a total transaction of $618,360.00. Following the sale, the chief executive officer now directly owns 95,328 shares in the company, valued at approximately $4,912,251.84. The disclosure for this sale can be found here. 2.48% of the stock is owned by corporate insiders.
Cambrex Corporation Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.